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4.6% -26.2% vs. 3.1% - 12.5%) was better with combination therapy vs. control 
group therapies. In two studies, patients on vandetinib and docetaxel combination 
therapy showed a significant improvement (p< 0·0001) in PFS and overall response 
rate versus those randomly assigned to receive docetaxel only. Results of meta- 
analysis demonstrate that combined targeted therapy has better OS (WMD: 1.23 
[95% CI: 0.06, 2.41], p = 0.04), PFS (WMD: 1.07 [95% CI: 0.7, 1.45], p < 0.00001) and 
ORR (OR: 1.85 [95% CI: 1.49, 2.31], p < 0.00001). The AE profile (gastrointestinal, 
vascular, infectious and blood disorders) was better in the control group thera-
pies. ConClusions: Survival benefit and response rate with combined inhibition 
therapy against EGFR and VEGF was better than the VEGF or EGFR alone inhibi-
tion. Combination therapy was associated with increased toxicity resulting in low 
compliance and dose reduction or discontinuation.
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A SyStemAtiC Review to ASSeSS the ASSoCiAtioN BetweeN the USe of 
ANtidePReSSANtS ANd mAle-oNly CANCeRS
Gupta J1, Sehgal M2
1PAREXEL International, New Delhi, India, 2PAREXEL International, Chandigarh, India
objeCtives: To assess the association between antidepressants (ADs) use and 
male-only cancers. Methods: Embase and PubMed were searched for relevant 
human studies published in English. Data was extracted for study population, study 
characteristics, interventions, and risk of male cancers (prostate [PC], testicular [TC], 
penile [PNC], and male breast cancer [MBC]). Results: Of the 374 results that were 
obtained from the literature search, five case-control studies (three assessed PC risk 
and two assessed TC risk) and one case-report (assessed MBC risk) met the inclu-
sion criteria. None of the included studies assessed PNC risk. In a population-based 
study, no significant association was found between selective serotonin reuptake 
inhibitors (SSRIs) use and PC (risk ratio [RR]= 1.01 [95% CI: 0.82-1.25]). Similarly, no 
significant association was found between ADs use and PC risk in other two stud-
ies. Significantly positive association was found between tricyclic antidepressants 
(TCAs) use for 2-5 years and PC with a RR of 1.31 (1.14-1.51), 1.58 (1.29-1.93), and 
2.42 (1.87-3.12) for the low, medium, and high average daily dose levels, respectively. 
However, authors acknowledged detection bias as possible reason for the observed 
association. SSRIs were found to be significantly associated with TC (fluoxetine 
RR= 2.51 [1.39-4.53]; paroxetine RR= 2.44 [1.25-4.74]) in one study. A four-year follow-
up study re-tested the association with 12 ADs. In multivariate analyses in this 
study, neither fluoxetine (odds ratio [OR]= 1.22 [0.88-1.71]) nor paroxetine (OR= 1.19 
[0.78-1.83]) or all SSRIs combined (OR= 1.21 [0.92-1.58]) were significantly associ-
ated with TC risk. All TCAs (OR= 1.06 [0.75-1.51]) and all ADs combined (OR= 1.06 
[0.85-1.32]) were also not associated with TC risk. In a report of three cases, authors 
reported an anecdotal association between SSRIs and MBC. ConClusions: The 
results do not indicate significant association between ADs use and risk of male-
only cancers. In most cases, weak positive associations disappeared after adjusting 
for confounding factors.
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SeRioUS PoSt-oPeRAtive iNfeCtioNS iNCReASe ReSoURCe UtiliZAtioN, 
leNGth of StAy, ANd iNPAtieNt moRtAlity iN PediAtRiC PAtieNtS 
UNdeRGoiNG BRAiN tUmoR ReSeCtioN
Van Doren BA, Noone J, Odum SM, Huet YM
University of North Carolina at Charlotte, Charlotte, NC, USA
objeCtives: To assess the impact that serious post-operative infections (SPOI) 
have on hospitalization outcomes (i.e., resource utilization, length of stay, 
and inpatient mortality) in pediatric patients undergoing brain tumor resec-
tion. Methods: Data from the 2003-2012 Nationwide Inpatient Samples (United 
States Agency for Healthcare Research & Quality) were analyzed for this study. 
Patients aged 20 and younger were eligible for inclusion if they had a malignant 
brain tumor (ICD-9 diagnosis codes 191.xx and/or 198.3) and underwent tumor 
resection (ICD-9 procedure code 01.59) during hospitalization. SPOI, including 
bacteremia (ICD-9 diagnosis code 790.7), septicemia (ICD-9 diagnosis code 038), 
pneumonia (ICD-9 diagnosis codes 481, 482, 483, 485, or 486), and wound infections 
(ICD-9 diagnosis codes 998.51 and/or 998.59) were also identified in the discharge 
summary. The impact of the serious SPOI on hospitalization outcomes were then 
assessed using bivariate and multivariate models. Results: A total of 7,845 pedi-
atric patients underwent brain tumor resection (Median Age: 8 years [IQR: 3-15]. Of 
these patients, 5.9% (N= 461) had a SPOI, of which septicemia/bacteremia was the 
most common (N= 312). SPOIs increased the odds of inpatient death nearly four-
fold (unadjusted OR: 3.76 [2.62-5.40], p< .0001). When adjusted for patient charac-
teristics, SPOIs were still associated with a nearly four-fold increase in the odds 
of inpatient mortality (adjusted OR: 3.73 [2.59-5.36]). Patients with SPOIs stayed 
significantly longer in the hospital (Median: 16 days [IQR: 6-33]) than those with-
out SPOIs (Median: 5 days [IQR: 3-10]) (p< .0001). On average, patients with SPOIs 
underwent four additional procedures during the hospitalization stay (Median: 6 
procedures [IQR: 2-8]) than those without SPOIs (Median: 2 procedures [IQR: 1-5]) 
(p< .0001). ConClusions: SPOIs significantly increase resource utilization, length 
of stay, and odds of inpatient mortality for pediatric patients undergoing brain 
tumor resection. Quality and process improvement efforts should be considered 
to minimize the risk of SPOIs in this patient population.
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ChANGeS iN the moRtAlity RAte dURiNG the lASt deCAde iN the fieldS 
of oNColoGy iN hUNGARy
Balázs T, Rakonczai P, Frigyesy R, Bacskai M
Healthware Consulting Ltd., Budapest, Hungary
objeCtives: Based on the data of the Hungarian Central Statistical Office the preva-
lence of oncological patients in Hungary is growing due to the modern diagnostic 
devices, the effectiveness of diagnostic screening methods and the increasing life 
expectancy. This study aims to assess information about the change in the mortality 
rate in the relevant patient population during the last decades. Methods: This ret-
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ASSeSSmeNt of SeRioUS AdveRSe ReACtioNS AmoNG PAtieNtS oN 
tyRoSiNe KiNASe iNhiBitoRS: ideNtifiCAtioN of SiGNifiCANt SiGNAlS 
foR GAStRoiNteStiNAl hemoRRhAGe ANd PUlmoNARy ReACtioNS
Raisch DW1, Chen C1, Arabyat R1, Rafi JA1, Bennett CL2
1University of New Mexico College of Pharmacy, Albuquerque, NM, USA, 2University of South 
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objeCtives: Tyrosine kinase inhibitors (TKIs) provide target-specific therapies for 
certain types of malignancies. TKIs may be associated with serious adverse drug 
reactions. We searched the Food and Drug Administration’s Adverse Event Reporting 
System (FAERS) to identify specific adverse drug reactions associated with small 
molecule TKIs in the post-marketing setting. Methods: The TKIs included were 
gefitinib, imatinib, lapatinib, nilotinib, erlotinib, pazopanib, sorafenib, and vande-
tanib. The adverse reactions evaluated were interstitial lung disease (ILD), pneumo-
nitis, pleural effusion, and gastrointestinal hemorrhage, depression, and suicide. 
We searched FAERS for each TKI from their respective approval date and calculated 
empiric Bayesian geometric means (EBGM) to identify significant disproportionality 
signals of each drug and reaction. Results: EBGM for ILD, pneumonitis, and pleu-
ral effusion were significant for gefitinib, imatinib, erlotinib, and sorafenib. EBGM 
for pleural effusion was also significant for nilotinib. The strongest EBGM signals 
were associated with gefitinib/ILD (25.4, n= 320), gefitinib/pneumonitis (10.5, n= 54), 
erlotinib/ILD (7.5, n= 212), nilotinib/pleural effusion (7.0, n= 101), erlotinib/pleural 
effusion (6.9, n= 325), sorafenib/pleural effusion (6.4, n= 70), imatinib/pleural effusion 
(6.3, n= 413), gefitinib/pleural effusion (5.8, n= 118), and erlotinib/pneumonitis (5.7, 
n= 63). EBGM for gastrointestinal bleeding was significant for erlotinib (2.5, n= 156) 
and sorafenib (4.3, n= 63). No significant signals were found for depression or suicide 
with any of the TKIs. Mortality rates for the adverse reactions with significant signals 
were: ILD= 50.8%, gastrointestinal bleeding= 40.6%, pneumonitis= 37.0%, and pleural 
effusion= 31.5%. ConClusions: Serious pulmonary adverse reactions, with high 
rates of mortality, have been reported disproportionately more frequently with gefi-
tinib, imatinib, erlotinib, nilotinib, and sorafenib. Gastrointestinal hemorrhage has 
been reported to FAERS disproportionately more often with erlotinib and sorafenib. 
Limitations of FAERS are that lack of signals among other TKIs may be due to less 
frequent use or reporting of these reactions to FAERS, or shorter post-marketing 
time periods. Physicians and pharmacists should inform and monitor patients on 
TKIs for these reactions.
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fACtoRS iNflUeNCiNG tReAtmeNt dURAtioN iN metAStAtiC ColoReCtiC 
CANCeR PAtieNtS tReAted with Ziv-AfliBeRCePt: A ReAl woRld view
Craver CW1, Belk K1, Blanchette CM2
1MedAssets, Mooresville, NC, USA, 2University of North Carolina at Charlotte, Charlotte, NC, USA
objeCtives: Ziv-aflibercept (Ziv) is an anti-angiogenic agent used in combination 
with FOLFIRI (folinic acid, fluorouracil and irinotecan) to treat adults with metastatic 
colorectal cancer (MCC). The purpose of this study is to examine the impact of patient 
characteristics, complications, and comorbidities on treatment patterns and out-
comes of Ziv-treated MCC patients in a real world setting. Methods: A retrospective 
cohort study was conducted on Ziv-FOLFIRI treated MCC patients in the MedAssets 
health system data for inpatient and outpatient visits between January 2012 and April 
2015. Age and gender, hospital characteristics, clinical comorbidities, and utilization 
measures (number of visits, treatment duration, and Ziv initiation) were described. 
Ziv related complications included neutropenia, proteinuria, hypertension, gastroin-
testinal (GI) hemorrhage, and thromboembolism. Multivariate regression models were 
developed to identify drivers of hospital utilization and treatment duration. Results: 
The study population included 337 patients that were predominately male (55.4%) 
with an average age of 58.8 years. The mean Charlson comorbidity score was 7.51. 
Hospital utilization included over 12,000 visits which occurred primarily in the out-
patient setting (96.2%) in teaching facilities (69.0%) with 300 or more beds (87.6%). 
Treatment complications included neutropenia (31.2%), proteinuria (6.2%), hyperten-
sion (48.7%), GI hemorrhage (7.4%), GI perforation (3.2%), and deep vein thrombosis 
(12.2%). Mean treatment duration was 523 days while the average days from colon 
cancer diagnosis to Ziv treatment was 218 days. After adjustments, neutropenia (HR: 
0.771, p= 0.0323) chronic renal disease (HR: 0.649, p= 0.001), and hypertension (HR: 
0.693, p= 0.001) were found to significantly reduce treatment duration. Neutropenia 
(RR: 0.23, p= 0.0135) and sever liver disease (RR: 0.035, p= 0.0008) had a significant 
impact on total visits. ConClusions: Ziv related complications and comorbidities 
can significantly impact treatment viability and ultimately patient survival.
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effiCACy ANd SAfety PRofile of ComBiNed tARGeted theRAPy  
AGAiNSt eGfR ANd veGf iN PAtieNtS with PRevioUSly tReAted 
AdvANCed NoN–SmAll-Cell lUNG CANCeR: A SyStemAtiC Review ANd 
metA-ANAlySiS
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objeCtives: The objective was to evaluate the clinical efficacy and safety of 
combined targeted therapy against EGFR and VEGF pathways in patients with 
previously treated advanced Non–small-cell lung cancer (NSCLC). Methods: 
Studies were retrieved from Embase, Pubmed and Cochrane databases using 
relevant search strategies. Randomized controlled trials which compared com-
bined targeted therapy with control groups (including single EGFR or VEGF inhi-
bition or/and chemotherapy) were selected as per pre-defined inclusion criteria. 
Outcomes assessed included overall survival (OS), progression free survival (PFS), 
objective response rate (ORR), and adverse events (AEs). Two reviewers indepen-
dently extracted data from the included studies. Data was analysed using RevMan 
(v5.3). Results: Of the 876 studies identified, seven studies with 3347 patients 
were included for meta-analysis. In total, 1688 patients were randomised to com-
bination therapy and 1659 were randomised to control groups. Median OS (range 
8- 13.7 vs. 4.5- 13.4 months), PFS (range 3.4- 4.7 vs. 1.9- 4.8 months) and ORR (range 
